Impact of Atopic Dermatitis on Patient Self-Reported Quality of Life, Productivity Loss, and Activity Impairment: An Analysis Using the National Health and Wellness Survey

Laurent Eckert1, Shaloo Gupta2, Caroline Amand, Abhiijit Gadkar1, Sunny Mahajan1
1Sanofi, Chilly-Mazarin, France; 2Kantar Health, Princeton, NJ, USA; 3Regenomix, Tarrytown, NY, USA; 4Sanofi, Bridgewater, NJ, USA

Table 1. Demographic and clinical characteristics of the AD and matched control cohort.

Table 2. QoL.

Table 3. Employment status and presenteeism.

Figure 1A. Caudal and sebaceous gland ducts

Figure 1B. Work and activity impairment assessed using the WPAI questionnaire in the AD and matched control cohorts.

Figure 2. Work and activity impairment in the AD and matched control cohorts assessed using the WPAI questionnaire.

Figure 3. Work and activity impairment in patients who self-reported AD severity.

REFERENCES


ACKNOWLEDGMENTS

Research sponsored by Sanofi and Regenonix Pharmaceuticals, Inc. Medical writing support provided by ej2.0 R&D (scientific and medical writing and editing services), Lone Star Scientific, Inc.

Disclosures

Laurent Eckert, MD, holds equity interest in Sanofi and Sanofi US. Sanofi seeks to prevent the conflict of interest while ensuring that all research is conducted with scientific integrity. Upon identifying a potential conflict, the company has taken steps to ensure that the integrity of the research is maintained.

Presented at the American Academy of Dermatology 75th Annual Meeting, March 4-8, 2016, Washington, DC